Compare FAF & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FAF | BLTE |
|---|---|---|
| Founded | 1889 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 6.5B |
| IPO Year | 2009 | 2021 |
| Metric | FAF | BLTE |
|---|---|---|
| Price | $58.12 | $150.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $78.50 | ★ $181.14 |
| AVG Volume (30 Days) | ★ 933.5K | 166.6K |
| Earning Date | 04-22-2026 | 03-02-2026 |
| Dividend Yield | ★ 3.87% | N/A |
| EPS Growth | ★ 376.19 | N/A |
| EPS | ★ 6.00 | N/A |
| Revenue | ★ $7,452,200,000.00 | N/A |
| Revenue This Year | $8.08 | N/A |
| Revenue Next Year | $5.46 | $363.39 |
| P/E Ratio | $9.46 | ★ N/A |
| Revenue Growth | ★ 21.61 | N/A |
| 52 Week Low | $53.95 | $49.00 |
| 52 Week High | $71.47 | $200.00 |
| Indicator | FAF | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 32.50 | 31.62 |
| Support Level | $54.07 | $148.78 |
| Resistance Level | $66.97 | $161.28 |
| Average True Range (ATR) | 2.02 | 7.74 |
| MACD | -1.16 | -2.81 |
| Stochastic Oscillator | 14.33 | 11.24 |
First American Financial Corp is a financial services business providing insurance through segments: Title insurance and related services segment include real estate insurance, property closing services, third-party handling of real estate funds (escrow), risk mitigation, real estate data products, and related real estate transaction services; The home warranty segment provides residential service contracts that cover residential systems, such as heating and air conditioning systems, and certain appliances against failures that occur as the result of normal usage during the coverage period; and The corporate segment includes investments in venture-stage companies, certain financing facilities and corporate services supporting the company's business operations.
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.